IRIS
PACELLI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.322
NA - Nord America 1.031
AS - Asia 970
SA - Sud America 154
AF - Africa 66
OC - Oceania 4
Totale 3.547
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 984
RU - Federazione Russa 411
IT - Italia 359
SG - Singapore 297
CN - Cina 266
IE - Irlanda 157
BR - Brasile 127
GB - Regno Unito 119
VN - Vietnam 91
HK - Hong Kong 68
KR - Corea 60
FR - Francia 59
DE - Germania 53
IN - India 50
BD - Bangladesh 45
FI - Finlandia 40
SE - Svezia 39
CA - Canada 30
ZA - Sudafrica 29
PK - Pakistan 18
NL - Olanda 17
UA - Ucraina 15
EG - Egitto 14
IQ - Iraq 14
MX - Messico 13
AR - Argentina 12
PL - Polonia 12
ES - Italia 11
IR - Iran 10
BE - Belgio 9
JP - Giappone 9
KE - Kenya 8
AT - Austria 6
SA - Arabia Saudita 6
MA - Marocco 5
TR - Turchia 5
AU - Australia 4
CZ - Repubblica Ceca 4
ID - Indonesia 4
UZ - Uzbekistan 4
CI - Costa d'Avorio 3
CO - Colombia 3
MY - Malesia 3
PY - Paraguay 3
TN - Tunisia 3
BO - Bolivia 2
CR - Costa Rica 2
DZ - Algeria 2
EC - Ecuador 2
GE - Georgia 2
JO - Giordania 2
KH - Cambogia 2
LK - Sri Lanka 2
NG - Nigeria 2
OM - Oman 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.547
Salva come PNG Salva come JPEG
Città #
Singapore 183
Dublin 154
Moscow 112
Dallas 109
San Jose 104
Hefei 101
Ashburn 95
Southend 81
Santa Clara 72
Hong Kong 64
Seoul 56
Siena 55
Beijing 47
Fairfield 45
Florence 41
Los Angeles 40
Chandler 34
Milan 33
New York 32
Ho Chi Minh City 29
Lauterbourg 28
Council Bluffs 26
Johannesburg 25
Munich 25
Helsinki 23
Ann Arbor 22
Rome 21
São Paulo 20
Houston 19
Seattle 19
Hanoi 18
Woodbridge 17
The Dalles 15
Bengaluru 14
Turin 14
Chennai 13
Shanghai 13
Cambridge 12
Toronto 12
London 11
Buffalo 9
Lappeenranta 9
Warsaw 9
Cairo 8
Denver 8
Dong Ket 8
Nuremberg 8
Orem 8
Princeton 8
Turku 8
Wilmington 8
Baghdad 7
Dearborn 7
Frankfurt am Main 7
Jacksonville 7
Montreal 7
Redondo Beach 7
Cagliari 6
Düsseldorf 6
Genoa 6
Atlanta 5
Brooklyn 5
Da Nang 5
Messina 5
Mumbai 5
Portsmouth 5
San Diego 5
Stockholm 5
Biên Hòa 4
Bologna 4
Boston 4
Brussels 4
Dhaka 4
Fano 4
Guangzhou 4
Nanjing 4
Padova 4
Paris 4
Phoenix 4
Pisa 4
Rio de Janeiro 4
Tashkent 4
Tokyo 4
Vancouver 4
Vienna 4
Abidjan 3
Brescia 3
Chicago 3
Colombo 3
Corsico 3
Curitiba 3
Gussago 3
Haiphong 3
Lahore 3
Lucknow 3
Miami 3
Mol 3
Palermo 3
Querétaro 3
San Mateo 3
Totale 2.158
Salva come PNG Salva come JPEG
Nome #
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 307
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 299
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 291
Evaluation of Multiple Myeloma Minimal Residual Disease by using Next Generation Flow in patients undergoing Daratumumab consolidation therapy 287
Anti CD38 monoclonal antibodies for multiple myeloma treatment 195
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 189
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 173
Drug resistance and minimal residual disease in multiple myeloma 154
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 153
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 152
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 148
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 141
Anti-BCMA novel therapies for multiple myeloma 137
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 136
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow 135
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 131
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 130
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies 129
“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow 129
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 86
Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience 60
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML) 29
Reply to “Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!” 26
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM 16
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response 7
Totale 3.640
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022103 6 6 3 0 8 1 3 13 11 13 25 14
2022/2023207 8 17 16 18 10 20 7 33 16 9 40 13
2023/2024406 22 20 33 30 30 67 118 16 4 21 15 30
2024/2025775 38 28 94 34 86 41 21 38 79 50 88 178
2025/20261.861 130 227 152 261 377 75 199 62 65 118 104 91
Totale 3.640